Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors

Inventors

Breitenbucher, James • Freestone, Graeme • Gomez, Laurent • Lemus, Robert • Ly, Kiev • McCarrick, Margaret • Vernier, William • VICKERS, Troy

Assignees

Dart Neuroscience LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9932345-B2

Patent

Publication Date

2018-04-03

Expiration Date


Abstract

The invention provides a chemical entity of Formula (I) wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods as disclosed herein, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

Core Innovation

The disclosure relates to substituted triazolo[1,5-a]pyrimidin-7-yl compounds and pharmaceutically acceptable salts thereof. The compounds are defined by Formula (I), including constraints on X, Y, and Z and substituent groups R1 and R2. The core scaffold includes 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl moieties attached to piperidine or morpholine frameworks, with carbonyl-linked aryl or heteroaryl groups and stereochemical variants in the exemplified set.

For Formula (I), X is —O— or —CH2—, Y is —CH2— or —CF2—, and Z is —CH2— or —C(=O)—. R1 is selected from phenyl, monocyclic or bicyclic heteroaromatic ring systems, and heterocycloalkyl rings, with defined substitution patterns and optional ring formation from two adjacent substituents. R2 is —C1-6 alkyl.

The document further provides selected groups of named triazolo[1,5-a]pyrimidin-7-yl derivatives, including piperidine and morpholine compounds bearing carbonyl-linked naphthalen-2-yl, quinolinyl, benzopyran, benzofuran, and other substituted aryl or heteroaryl moieties. The examples include stereochemically defined members such as (3R), (3S), (2R), and (2S) compounds, together with reported characterization data including 1H NMR and [M+H]+ values.

Claims Coverage

The consolidated claim coverage includes independent claims directed to Formula (I) compounds and independent claims directed to selected groups of specifically named triazolo[1,5-a]pyrimidin-7-yl derivatives. Across these claims, there are three main inventive features: the Formula (I) scaffold with constrained X, Y, and Z; the allowed R1 and R2 substituent classes; and the enumerated selected compounds, including stereochemical designations and pharmaceutically acceptable salts.

Formula (I) scaffold with constrained X, Y, and Z

A compound of Formula (I) or pharmaceutically acceptable salts thereof, wherein X is —O— or —CH2—; Y is —CH2— or —CF2—; and Z is —CH2— or —C(=O)—.

Allowed R1 and R2 substituent classes

R1 is selected from phenyl unsubstituted or substituted with one to five Ra members, monocyclic or bicyclic heteroaromatic rings substituted with one to four Rc members, and heterocycloalkyl rings substituted with one or more —F or —OCH3, and R2 is —C1-6 alkyl.

Selected triazolo[1,5-a]pyrimidin-7-yl derivatives

A compound selected from named substituted triazolo[1,5-a]pyrimidin-7-yl piperidine and morpholine derivatives, including carbonyl-linked aryl or heteroaryl substituents, benzyl-linked piperidine derivatives, stereochemical variants, and pharmaceutically acceptable salts thereof.

The claim coverage centers on Formula (I) compounds with defined X, Y, Z, R1, and R2 limits, together with selected named triazolo[1,5-a]pyrimidin-7-yl derivatives that feature piperidine or morpholine cores and substituted aryl or heteroaryl groups. The selected-compound claims also include stereochemical variants and pharmaceutically acceptable salts.

Stated Advantages

Not explicitly described in patent.

Documented Applications

Not explicitly described in patent.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.